Improvements to the delivery of these therapeutics will also continue, to be achieved by improved long-term expression vectors for gene delivery [23], by targeting the IL-27 to other conditions in other current ongoing projects, which include anti-inflammatory approaches for arthritis and for treating respiratory-distress-related conditions. This evidence concerns the gene IL27 and arthritic joint disease.